Use of the Ranger Paclitaxel-Coated Balloon in Patients With Chronic Limb-Threatening Ischemia: Short-Term Safety and Efficacy Results From Singapore

The prevalence of peripheral artery disease (PAD) increased by a quarter between 2000 and 2010, with 200 million estimated to have PAD globally.1 Primary drivers of this increase have been longer life expectancy1 and a diabetic epidemic.2 Chronic limb-threatening ischemia, also known as critical limb ischemia (CLI), is the most advanced stage of PAD, defined by the presence of PAD in combination with rest pain, gangrene, or lower-limb ulceration of more than 2-week duration.3 Despite no proven superiority over open surgical revascularization in terms of amputation-free survival (AFS) and overall mortality,4 an endovascular-first revascularization strategy is recommended for lower-limb arterial short occlusions or stenotic lesions Abstract